ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida
ZEO ScientifiX (OTCQB:ZEOX) is positioning itself for growth following Florida's new SB-1768 stem cell law, which authorizes the use of non-FDA-approved stem cell therapies for certain conditions. The company has launched strategic initiatives including:
The company's platform includes ethically sourced biologics developed in an FDA-registered, cGMP-compliant facility. To support its expansion, ZEO has launched a new website and partnered with Plus4 Public Relations and Small Circle creative agency to strengthen its market presence.
Under interim CEO Ian Bothwell's leadership, ZEO aims to establish industry standards through its product platform, partnerships, and physician education initiatives as Florida opens its regenerative medicine market.
ZEO ScientifiX (OTCQB:ZEOX) si sta preparando per la crescita grazie alla nuova legge della Florida SB-1768 sulle cellule staminali, che autorizza l'uso di terapie con cellule staminali non approvate dalla FDA per determinate condizioni. L'azienda ha avviato iniziative strategiche tra cui:
La piattaforma aziendale include biologici eticamente ottenuti sviluppati in una struttura registrata FDA e conforme alle normative cGMP. Per supportare la sua espansione, ZEO ha lanciato un nuovo sito web e ha collaborato con Plus4 Public Relations e l'agenzia creativa Small Circle per rafforzare la sua presenza sul mercato.
Sotto la guida dell'amministratore delegato ad interim Ian Bothwell, ZEO punta a stabilire standard di settore attraverso la sua piattaforma di prodotti, le partnership e le iniziative di formazione per medici, mentre la Florida apre il suo mercato della medicina rigenerativa.
ZEO ScientifiX (OTCQB:ZEOX) se está posicionando para el crecimiento tras la nueva ley SB-1768 de Florida sobre células madre, que autoriza el uso de terapias con células madre no aprobadas por la FDA para ciertas condiciones. La empresa ha lanzado iniciativas estratégicas que incluyen:
La plataforma de la compañía incluye biológicos obtenidos éticamente desarrollados en una instalación registrada por la FDA y conforme a cGMP. Para apoyar su expansión, ZEO ha lanzado un nuevo sitio web y se ha asociado con Plus4 Public Relations y la agencia creativa Small Circle para fortalecer su presencia en el mercado.
Bajo el liderazgo del CEO interino Ian Bothwell, ZEO busca establecer estándares en la industria a través de su plataforma de productos, asociaciones e iniciativas de educación para médicos, mientras Florida abre su mercado de medicina regenerativa.
ZEO ScientifiX (OTCQB:ZEOX)는 플로리다주의 새로운 SB-1768 줄기세포 법률에 따라 성장을 준비하고 있습니다. 이 법은 특정 조건에 대해 FDA 승인받지 않은 줄기세포 치료법의 사용을 허용합니다. 회사는 다음과 같은 전략적 이니셔티브를 시작했습니다:
회사의 플랫폼에는 FDA 등록 및 cGMP 준수 시설에서 개발된 윤리적으로 공급된 생물학적 제제가 포함되어 있습니다. 확장을 지원하기 위해 ZEO는 새로운 웹사이트를 출시하고 Plus4 Public Relations 및 Small Circle 크리에이티브 에이전시와 협력하여 시장 입지를 강화했습니다.
임시 CEO Ian Bothwell의 리더십 아래, ZEO는 플로리다가 재생 의학 시장을 개방함에 따라 제품 플랫폼, 파트너십 및 의사 교육 이니셔티브를 통해 산업 표준을 확립하는 것을 목표로 하고 있습니다.
ZEO ScientifiX (OTCQB:ZEOX) se positionne pour une croissance suite à la nouvelle loi SB-1768 de la Floride sur les cellules souches, qui autorise l'utilisation de thérapies à base de cellules souches non approuvées par la FDA pour certaines conditions. L'entreprise a lancé des initiatives stratégiques comprenant :
La plateforme de la société inclut des biologiques issus de sources éthiques développés dans une installation enregistrée auprès de la FDA et conforme aux normes cGMP. Pour soutenir son expansion, ZEO a lancé un nouveau site web et s'est associée à Plus4 Public Relations et à l'agence créative Small Circle afin de renforcer sa présence sur le marché.
Sous la direction du PDG par intérim Ian Bothwell, ZEO vise à établir des standards industriels grâce à sa plateforme de produits, ses partenariats et ses initiatives de formation des médecins, alors que la Floride ouvre son marché de la médecine régénérative.
ZEO ScientifiX (OTCQB:ZEOX) positioniert sich für Wachstum nach dem neuen SB-1768 Stammzellgesetz in Florida, das die Verwendung von nicht von der FDA zugelassenen Stammzelltherapien für bestimmte Erkrankungen erlaubt. Das Unternehmen hat strategische Initiativen gestartet, darunter:
Die Plattform des Unternehmens umfasst ethisch gewonnene Biologika, die in einer FDA-registrierten, cGMP-konformen Einrichtung entwickelt wurden. Zur Unterstützung der Expansion hat ZEO eine neue Webseite gestartet und Partnerschaften mit Plus4 Public Relations und der Kreativagentur Small Circle geschlossen, um die Marktpräsenz zu stärken.
Unter der Führung des Interims-CEO Ian Bothwell strebt ZEO an, durch seine Produktplattform, Partnerschaften und Ärztefortbildungsinitiativen Branchenstandards zu setzen, während Florida seinen Markt für regenerative Medizin öffnet.
- Strategic positioning to capitalize on Florida's new stem cell therapy market
- Established FDA-registered, cGMP-compliant facility for biologics production
- Launch of comprehensive physician education initiatives for regulatory compliance
- New strategic partnerships with PR and creative agencies for market expansion
- Currently operating under interim CEO leadership
- Products are non-FDA-approved, limiting potential market reach
- Market opportunity currently limited to Florida state
ZEO Launches New Website and Agency Partnerships to Address Expected Biologics Market Demand Following Florida's New Stem Cell Law
FORT LAUDERDALE, FL / ACCESS Newswire / July 9, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company pioneering the development of innovative biological therapeutics, is spearheading an expansion initiative aligned with the implementation of Florida's new SB-1768 stem cell law. With Florida now authorizing the use of non-FDA-approved stem cell therapies that are compliant with the new regulations for the treatment of certain defined conditions, ZEO is seeking to take advantage of the opportunity to set what it believes will be the industry standard through its product platform, new agency partnerships and educational initiatives.
The Future of Regenerative Medicine is Now
ZEO's turnkey product platform consists of a proprietary suite of ethically sourced biologics, developed and processed in a state-of-the-art FDA-registered, cGMP-compliant facility and physician education initiatives to assist Florida physicians in delivering regenerative care safely and compliantly under the new Florida guidelines. With an inventory of safe, regulatory-compliant biologics, a history of first-class research and competitive pricing, ZEO believes it is uniquely positioned to lead Florida's new era of accessibility and innovation in the biologics market.
"We believe that ZEO is entering into a new chapter of growth and expect additional states to join Florida in recognizing the therapeutic potential of regenerative biologics," said Ian Bothwell, interim chief executive officer of ZEO ScientifiX. "We're not just ready for this shift, we've built the product platform, partnerships and scientific roadmap to lead it."
With an expanding product pipeline, physician education initiatives and a strong compliance focus, ZEO is positioning itself as the go-to source for safe, effective and ethically developed regenerative therapies that have been legally approved.
ZEO Launches New Website to Reflect Market Evolution
In conjunction with the July 1, 2025, effective date of the new Florida legislation, ZEO has unveiled a newly redesigned website at www.zeoscientifix.com. The new platform highlights the Company's commitment to education, compliance and long-term therapeutic innovation - offering streamlined access to clinical data, physician resources and product information.
Strategic Agency Partnerships Support National Brand Presence
To further support this next phase of growth, ZEO ScientifiX has partnered with two key agencies:
Plus4 Public Relations, a national firm specializing in earned media, content development and strategic communications;
Small Circle, a full-service creative agency focused on brand identity, design and audience resonance.
ZEO believes that these partnerships will help them amplify their message and elevate their presence across emerging regenerative medicine markets in Florida and other states, when and where applicable.
About ZEO ScientifiX, Inc.
ZEO ScientifiX, Inc. (OTCQB:ZEOX) is not just committed to maintaining pace with regulatory change - our goal is to set the standard. As a clinical-stage biopharmaceutical company focused on the development of biological therapeutic platforms, we believe that when physicians are educated, patients are better served - and innovation thrives. We are driven by a commitment to advance the frontiers of regenerative medicine and biologic therapeutics, delivering meaningful solutions for patients and providers worldwide. Our proprietary products, including (a) Zofin™, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles, and (b) Patient Pure X™ ("PPX™"), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood, are manufactured in an FDA-registered, cGMP-compliant laboratory. To learn more, please visit https://zeoscientifix.com.
Forward-Looking Statements
Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will," "believes," "expects," "potential," or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Florida Stem Cell Law will be beneficial to the Company or any initiatives related to this new law will increase our revenues and/or the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations, including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically disclaims any duty to update the information in this press release.
Contact Information
Chloe Detrick
Plus4 Public Relations
chloe@plus4pr.com
SOURCE: ZEO ScientifiX, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the impact of Florida's SB-1768 law on ZEO ScientifiX (ZEOX)?
What facilities and compliance measures does ZEO ScientifiX (ZEOX) have in place?
Who is currently leading ZEO ScientifiX (ZEOX)?
What strategic partnerships has ZEO ScientifiX (ZEOX) announced?
Where can investors find information about ZEO ScientifiX (ZEOX)?
